Cart
sales@molnova.com
Ipafricept
CAS No. 1391727-24-4
Ipafricept( —— )
Catalog No. M36801 CAS No. 1391727-24-4
Ipafricept (OMP-54F28) is a recombinant fusion protein consisting of the extracellular portion of the human frizzled-8 receptor fused to a fragment of human IgG1 Fc, and a Wnt inhibitor that blocks Wnt signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 780 | Get Quote |
|
| 5MG | 1264 | Get Quote |
|
| 10MG | 2024 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIpafricept
-
NoteResearch use only, not for human use.
-
Brief DescriptionIpafricept (OMP-54F28) is a recombinant fusion protein consisting of the extracellular portion of the human frizzled-8 receptor fused to a fragment of human IgG1 Fc, and a Wnt inhibitor that blocks Wnt signaling.
-
DescriptionIpafricept (OMP-54F28; FZD8-Fc) is the first class of recombinant fusion proteins, consisting of the extracellular portion of the human fried-8 receptor fused to the Fc fragment of human IgG1 binding to the Wnt ligand. Ipafricept shows solid tumor inhibition activity, with well tolerance.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
RecptorWnt/beta-catenin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1391727-24-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jimeno A, et al. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. ?
molnova catalog
related products
-
FIDAS-3
FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?
-
Hematein
Hematein inhibits Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway, and increases apoptosis in lung cancer cells.
-
DIF-3
DIF-3 is a chemical compound that acts by activating GSK-3β to facilitate the degradation of cyclin D1 and c-Myc, resulting in reduced expression levels of these proteins.
